Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 27;19(5):23.
doi: 10.1007/s11892-019-1140-7.

Economics of Genetic Testing for Diabetes

Rochelle Naylor  1
Affiliations
Review

Economics of Genetic Testing for Diabetes

Rochelle Naylor. Curr Diab Rep. .

Abstract

Purpose of review: Monogenic diabetes is an uncommon but important form of diabetes, with the most common causes benefitting from management that accounts for the genetic mutation. This often results in decreased costs and treatment burden for affected individuals. Misdiagnosis as type 1 and type 2 diabetes is common. Given the significant burden of diabetes costs to the healthcare system, it is important to assess the economic impact of incorporating genetic testing for monogenic diabetes into clinical care through formal cost-effectiveness analyses (CEAs). This article briefly summarizes the barriers to timely monogenic diabetes diagnosis and then summarizes findings from CEAs on genetic testing for monogenic diabetes.

Recent findings: CEAs have shown that routine genetic testing of all patients with a clinical diagnosis of type 1 diabetes can be cost-saving when applied to the scenarios of neonatal diabetes or in a pediatric population. Routine screening has not been shown to be cost-effective in adult populations. However, next-generation sequencing strategies and applying biomarkers to identify and limit genetic testing to people most likely to have monogenic diabetes are promising ways to make testing strategies cost-effective. CEAs have shown that genetic testing for monogenic diabetes diagnosis can be cost-effective or cost-saving and should guide insurers to consider broader coverage of these tests, which would lead to accurate and timely diagnosis and impact treatment and clinical outcomes.

Keywords: CEA; Cost-effectiveness; Genetic testing; MODY; Monogenic diabetes.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest The author declares that she has no conflict of interest.

References

    1. American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. American Diabetes Association. 2018;41(5):917–28. - PMC - PubMed
    1. American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care. American Diabetes Association. 2016;40(Supplement 1):S11–24. - PubMed
    1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. Springer-Verlag. 2012;55(6):1577–96. - PubMed
    1. Raz I, Riddle MC, Rosenstock J, Buse JB, Inzucchi SE, Home PD, et al. Personalized management of hyperglycemia in type 2 diabetes: reflections from a diabetes care editors’ expert forum. Diabetes Care American Diabetes Association. 2013;36(6):1779–88. - PMC - PubMed
    1. Bacon S, Kyithar MP, Rizvi SR, Donnelly E, McCarthy A, Burke M, et al. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort. Diabet Med. 2016;33(7):976–84. - PubMed